The Impact of Type2Inflammation on the Neuroimmune Axis in AD
Dermatology
Dr. Gil Yosipovitch discussed the interaction between type2inflammation and itch in AD, the role of type2inflammation on neuroarchitecture, and the role of type2 cytokines in neuronal sensitization.
ERS 2024 | Unraveling the Role of Type2Inflammation in COPD
Pulmonology
Professor Mona Bafadhel presents a comprehensive overview of type2inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type2Inflammation
Pulmonology
Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type2inflammation and review current and emerging biologic therapies
Why targeting Type2Inflammation is important in the treatment of skin diseases like AD, PN and CSU
Dermatology
Dr. Palomares discusses how type2inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.
IRS-ISIAN 2024 | Targeting Type2Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP
Rhinology
Prof. Joaquim Mullol reports on biologic improvements in sense of smell and nasal congestion in patients with and without a history of endoscopic sinus surgery.
How Does Protective Type2 Immunity Become Harmful Type2Inflammation?
Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type2 immunity can become dysregulated, leading to harmful type2inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
Type2Inflammation in AD Manifestations in Skin and Body
Dermatology
Dr. Ramien discusses the role of type2inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.